Kalaris <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Initial Phase 1a Results for TH103 in Neovascular <a href="https://laohu8.com/S/AMD">AMD</a>
Kalaris Therapeutics Inc. announced positive initial results from its Phase 1a single ascending dose trial of TH103, a fully humanized recombinant fusion protein targeting VEGF, in treatment-naïve patients with neovascular age-related macular degeneration (nAMD). The data showed a mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at one month following a single injection. TH103 was generally well tolerated, and pharmacokinetic analysis indicated a 27 to 51-fold lower plasma Cmax compared to current leading agents, suggesting increased intraocular retention. The results were presented during a live webcast and conference call on December 17, 2025. Kalaris is continuing enrollment in an ongoing Phase 1b/2 multi-ascending dose study, with preliminary efficacy and safety data expected in the second half of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9604003) on December 17, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。